Podcasts about pulmonary vascular disease

Craig Thompson is the Chief Executive Officer of Cerevance ( https://www.cerevance.com/about ), a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company's proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology, a machine learning platform that helps measure precise levels at which thousands of genes are expressed in any cell type in any region of the brain, and then map those genes to specific diseased and healthy brain states. Most recently, Mr. Thompson was President and Chief Executive Officer of Neurana Pharmaceuticals. Prior to Neurana, Mr. Thompson was President and Chief Executive Officer of Anthera Pharmaceuticals. Mr. Thompson's previous biotech experience includes Chief Operating Officer for Tetraphase Pharmaceuticals and Chief Commercial Officer for Trius Therapeutics where he was involved in the $707M up front acquisition of Trius by Cubist Pharmaceuticals, as well as a partnership with Bayer Pharma AG. Prior to Trius, Mr. Thompson served in various global and U.S. roles at Pfizer Inc., including Therapeutic Group Leader of Allergy, Respiratory, Pulmonary Vascular Disease and Inflammation; and ultimately served as Vice President of Marketing for Pfizer's Specialty Care Business Unit. Previous to Pfizer, Mr. Thompson served in positions of increasing responsibility at Merck & Co., Inc including leading the partnership with Schering Plough. Mr. Thompson holds a Bachelor's degree in Commerce from McMaster University and an M.B.A. from the University of Notre Dame. Support the show

Kristina Kudelko, MD, is the Director of Education and Stanford's Vera Moulton Wall Center. She discusses the 23rd annual #RaceAgainstPH, how it raises awareness and funds for this devastating rare disease and the importance of PH Courage Award winners.  Don't miss the 23rd Annual Race Against PH at November 5 hosted by the Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford. Click here to learn more. #raceagainstph @phaatstanford Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com 

In this episode, pulmonary hypertension patient and Stanford's Race Against PH 2023 Adult PH Courage Award recipient, Kendra Meneghetti, discusses her lifelong battle with PH, the challenge of receiving a transplant during Covid, and how her band provides a unique outlet by releasing her trauma through music. Don't miss the 23rd Annual Race Against PH at November 5 hosted by the Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford. Click here to learn more. #raceagainstph @phaatstanford Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com 

Synopsis: Craig Thompson is the CEO of Cerevance, a clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system diseases. He discusses the arc of his career, beginning at big pharma at Merck and Pfizer before transitioning to biotech, and his learnings along the way. As CEO, he shares what he's learned about developing a relationship with his board and the value they bring to his company. He also talks about the current CNS landscape, where Cerevance is from a development perspective, and the unique way the company approaches AI. Biography: Craig Thompson is the Chief Executive Officer of Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company's proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform. Most recently, Mr. Thompson was President and Chief Executive Officer of Neurana Pharmaceuticals. Prior to Neurana, Mr. Thompson was President and Chief Executive Officer of Anthera Pharmaceuticals. His previous biotech experience includes Chief Operating Officer for Tetraphase Pharmaceuticals and Chief Commercial Officer for Trius Therapeutics where he was involved in the $707M up front acquisition of Trius by Cubist Pharmaceuticals, as well as a partnership with Bayer Pharma AG. Prior to Trius, Mr. Thompson served in various global and U.S. roles at Pfizer Inc., including Therapeutic Group Leader of Allergy, Respiratory, Pulmonary Vascular Disease and Inflammation; and ultimately served as Vice President of Marketing for Pfizer's Specialty Care Business Unit. Previous to Pfizer, Mr. Thompson served in positions of increasing responsibility at Merck & Co., Inc including leading the partnership with Schering Plough. Mr. Thompson holds a Bachelor's degree in Commerce from McMaster University and an M.B.A. from the University of Notre Dame.

In this episode, pulmonary hypertension patient and @PHatStanford #RaceAgainstPH 2022 Pediatric PH Courage Award recipient, Paige Zils (10) and her mother Lindsey Doolan, discuss Paige's PH diagnosis and the importance of a great care team. Don't miss the 22nd Annual Race Against PH at November 22 hosted by the Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford. Click here to learn more.   Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com

In this episode, pulmonary hypertension patient and Stanford's Race Against PH 2022 Adult PH Courage Award recipient, Yolanda Villalon, discusses her devastating diagnosis and the impact on  finding the right support group. Don't miss the 22nd Annual Race Against PH at November 22 hosted by the Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford. Click here to learn more. #raceagainstph @phaatstanford Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com

In this episode, pulmonary hypertension patient and Stanford's Race Against PH 2021 Adult PH Courage Award recipient, Graydon Cawein, discusses his long road to his rare disease diagnosis, survivor's guilt, and the importance of finding an expert treatment center. Don't miss the 22nd Annual Race Against PH at November 22 hosted by the Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford. Click here to learn more. #raceagainstph @phaatstanford Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com

Yon Sung, MD is a Clinical Assistant Professor of Pulmonary & Critical Care at Stanford University School of Medicine and specializes in the care of pulmonary hypertension patients. She also serves as the Director of Community Outreach for the Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford and in this position, has the goal of increasing awareness of PH and providing clinical support and education to clinicians and patients alike. In this episode, she discusses the 19th Annual Race Against PH 5K, taking place at Stanford on November 3rd, 2019 Register for the 19th Annual Race Against PH 5K: med.stanford.edu/raceagainstph Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Never miss an episode with the phaware® podcast app. Follow us @phaware on Facebook, Twitter, Instagram, YouTube & Linkedin Engage for a cure: www.phaware.global/donate #phaware #ClinicalTrials @antidote_me 

Tiffany Olka, RN gives an overview of the University of Minnesota Medical Center's Center for Pulmonary Vascular Disease and Right Heart Failure. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Never miss an episode with the phaware® podcast app. Follow us @phaware on Facebook, Twitter, Instagram, YouTube & Linkedin Engage for a cure: www.phaware.global/donate #phaware #ClinicalTrials @antidote_me @UMNHealth

Dr. Rabinovitch joined Stanford University School of Medicine Faculty in the summer of 2002 as the Dwight and Vera Dunlevie Professor of Pediatric Cardiology, and Scientist at the Vera Moulton Wall Center for Pulmonary Vascular Disease. The main focus of her research program is on uncovering molecular pathways that lead to developmental and inflammatory mechanisms of vascular pathobiology, particularly pulmonary hypertension. In this episode, Dr. Rabinovitch discusses the importance of pediatric pulmonary hypertension research efforts. Learn more about pulmonary hypertension at www.phaware365.global. Never miss an episode with the phaware® podcast app. Follow us @phaware on facebook, twitter, instagram, youtube & linkedin Engage for a cure: www.phaware.global/donate #phaware #phawareMD

The Race Against PH was started in 2001 by Katie Davis, Eddie Davis and Paige Dunn to promote awareness to the devastating disease Katie’s mother was battling. The 17th Annual Race Against PH 5k takes place on November 5th, 2017 at 9 a.m. at Stanford’s Pac-12 Plaza. Proceeds benefit the Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford and support research and efforts dedicated to finding new treatments and, ultimately, a cure for PH. Learn more about pulmonary hypertension at phaware365.global. Never miss an episode with the phaware® podcast app. Follow us on facebook, twitter, instagram, youtube & linkedin @phaware #phaware 

De test met zes minutenloopafstand levert veel en voldoende informatie voor patiënten met pulmonale hypertensie (PH) en het beloop van de ziekte. De 'ingewikkelde' fietstest met metingen van de ademhalingsgassen voegt dan vaak maar weinig toe. Aldus bewegingswetenschapper en tevens hoofd van de functie afdeling longziekten VUmc Herman Groepenhoff in zijn onderzoek naar welke parameters een goede voorspellende waarde hebben over het beloop van de ziekte PH. Promotor: prof.dr. A. Vonk Noordegraaf, dr. H.J. Bogaard. Faculteit: VU medisch centrum. Datum: 24-05-2013

De test met zes minutenloopafstand levert veel en voldoende informatie voor patiënten met pulmonale hypertensie (PH) en het beloop van de ziekte. De 'ingewikkelde' fietstest met metingen van de ademhalingsgassen voegt dan vaak maar weinig toe. Aldus bewegingswetenschapper en tevens hoofd van de functie afdeling longziekten VUmc Herman Groepenhoff in zijn onderzoek naar welke parameters een goede voorspellende waarde hebben over het beloop van de ziekte PH. Promotor: prof.dr. A. Vonk Noordegraaf, dr. H.J. Bogaard. Faculteit: VU medisch centrum. Datum: 24-05-2013

In the February 2012 European Respiratory Journal (ERJ) podcast, ERJ co-Chief Editor Anh Tuan Dinh-Xuan talks to Marc Humbert, Chief Editor of the European Respiratory Review, about three articles in the ERJ that extend our knowledge of the pulmonary circulation.

Click here for audio of lecture.